Naya Biosciences To Acquire Florida Biotechnologies For $20M Shares Of NAYA Post-Merger With INVO; Florida Biotechnologies Eligible For Additional $5M Upon Certain Milestones Achievement
Naya Biosciences To Acquire Florida Biotechnologies For $20M Shares Of NAYA Post-Merger With INVO; Florida Biotechnologies Eligible For Additional $5M Upon Certain Milestones Achievement
Naya Biosciences將在與INVO合併後以2,000萬美元的NAYA股份收購佛羅里達生物技術公司；佛羅里達生物技術公司在取得某些里程碑成就後有資格獲得額外500萬美元的額外500萬美元
- NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial
- Program developed by Florida Biotechnologies, Inc. & the University of Miami's Bascom Palmer Eye Institute
- NAYA continuing to implement acquisition roll-up of clinical and commercial assets in oncology, regenerative medicine, and fertility
- NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 following the recent filing of S-4 and joint draft proxy statements
- 在28名患者的臨床試驗顯示出初步安全性後，NAYA將加快II期臨床開發和患者早期就診
- 該項目由佛羅里達生物技術公司和邁阿密大學巴斯科姆·帕爾默眼科研究所開發
- NAYA繼續實施腫瘤學、再生醫學和生育領域臨床和商業資產的收購彙總
- 在最近提交了S-4和聯合委託書草案之後，NAYA預計將在2024年第一季度完成先前宣佈的與INVO Bioscience（納斯達克股票代碼：INVO）的合併